Navigation Links
Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
Date:9/18/2009

SAN FRANCISCO, Sept. 18 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced the Second and final closing of a private placement financing with aggregate gross proceeds of US $5,611,475, exceeding the target of US $5 million.

As previously reported, the net proceeds of the private placement will be used to continue advancing the Company's clinical development programs with the lead product JX-594. Key value creating milestones planned for the next 12 months include completion of a randomized Phase II trial in liver cancer, followed by initiation of a pivotal Phase III trial in liver cancer. In addition, Jennerex plans to complete a Phase I trial in solid cancers (including lung and colorectal), followed by initiation of a Phase II colorectal cancer trial. Proceeds will also be used for manufacturing, general corporate purposes and to augment working capital.

"This Series C was a success due both to continued investment from many of our current Shareholders, as well as support from a number of important new investors. We are particularly pleased to welcome the Ottawa Regional Cancer Foundation as a significant new investor," said David H. Kirn, M.D., President and CEO. "Jennerex and the Foundation share a common vision of extending and preserving the lives of patients with cancer. We also share a common commitment to build on the great strength of biological research and world-class facilities at the Ottawa Hospital Research Institute (OHRI). The Cancer Foundation's participation will further support and extend the scope of joint research and development activities being undertaken in partnership with Jennerex at the OHRI, including expansion of manufacturing and clinical trial activities," said Dr. Kirn.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Jennerex Closes $5 Million First Tranche of Series C Financing
2. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
5. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
6. Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
7. EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application
8. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
9. ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development
10. Pacific Biometrics Completes $4 Million Debt Financing
11. Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 News Facts ... India devoted to genome-based research for human health ... is taking a bite out of oral cancer with ... in India with the help of ... DataDirect Networks (DDN). , To fuel its cutting-edge cancer ...
(Date:9/23/2014)... BOSTON, Mass. (PRWEB) September 23, 2014 ... driven by Semantic Web technology, was named in the ... by Gartner, Inc. , The report details key ... category. , According to Gartner analysts Michael Shanler ... help accelerate innovation activities, expose complex relationships with scientific ...
(Date:9/23/2014)... TX (PRWEB) September 23, 2014 Texas ... fertility clinic in South Austin, expanding a Central Texas ... and San Antonio. The satellite office for the region’s ... andrology options to the South Austin, Buda, Kyle and ... effective and affordable fertility treatment directly to individuals and ...
(Date:9/23/2014)... 23, 2014 Healthcare professionals, ... will convene at the Society for Integrative ... held October 26-28 in Houston, Texas to ... practice in individualized integrative cancer care. This ... psychologists, nutritionists, naturopaths, acupuncturists, and other complementary ...
Breaking Biology Technology:National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 5Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 3International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3
... Feb. 24 Nektar Therapeutics,(Nasdaq: NKTR ... fourth quarter and,year ended December 31, 2008. , ... year for Nektar," said Howard W. Robin,President and ... unique polymer,conjugation chemistry platform, we advanced numerous proprietary ...
... and Play Capability of MyMedicalRecords Pro to ... Technology Experts Expected at HIMSS09LOS ANGELES, Feb. ... Bulletin Board: FVRL), which through its wholly-owned ... consumer-controlled Personal Health Records ("PHRs") ( www.mymedicalrecords.com ...
... Feb. 24 Particle Sciences Inc. today announced the ... from tissue hydration to the passivation of medical device ... series of patent-pending polymers that allow Particle Sciences to ... PS, Director of New Technologies.Particle Sciences has already used ...
Cached Biology Technology:Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 7Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 8Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 9MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 2MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 3MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 4MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 5Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System 2
(Date:9/22/2014)... Yale University researchers are studying a potential new ... respiratory disease in which scars develop in the lungs ... microRNA mimic, miR-29, which is delivered to lung tissue ... fibrosis, it reversed fibrosis after several days. , ... EMBO Molecular Medicine . , "The mimic, when ...
(Date:9/22/2014)... New Rochelle, NY, September 22, 2014Cassava, also known as ... high yields in areas of Africa, Asia, and Latin ... With the availability of novel enzymes and processes designed ... then be used to produce sweeteners such as glucose, ... alternative to corn, as described in a Review article ...
(Date:9/22/2014)... manufacture their own "antifreeze" proteins to survive in ... side effect, researchers report: The protein-bound ice crystals ... when temperatures warm. , The finding is ... Academy of Sciences . , "We discovered what ... evolution of antifreeze proteins in Antarctic notothenioid fishes," ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3
... Honeybees can learn to avoid nectar containing natural plant ... scientists at Newcastle University have found. This means that ... such as almond or apple orchards bees struggle to find ... toxic nectar. With honeybee populations already under stress, the Newcastle ...
... NEW YORK CITY (December 20, 2010)The New York Stem ... member of the inaugural class of NYSCF-Robertson Investigators, who was ... the December 27, 2010 Person of the Year Issue. ... School, was lauded for his discovery of an innovative method ...
... environmental factors cause the diversityor numberof species to increase ... suggested that species diversity continues instead of entering into ... in the Caribbean not only supports the original theory ... resources all work together to achieve equilibrium; it builds ...
Cached Biology News:Bee challenged -- toxin-laden nectar poses problems for honeybees 2Time Magazine names Derrick Rossi to 2010 list of 'People Who Mattered' 2Research shows that environmental factors limit species diversity 2
...
... offers the most comprehensive, cost-effective solution ... have incorporated unprecedented quality into both ... includes proven detection chemistries and antibodies ... TechMate protocol. It also includes our ...
... (X/R) Red System consists of concentrated ... and X/R Red Buffer. The X/R ... to produce red staining that may ... , Buffer, 100 mL , Chromogen, ...
Human Cell Line Slides...
Biology Products: